ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors

Publisher： Karger

E-ISSN： 1423-0313|96|3-4|163-166

ISSN： 0031-7012

Source： Pharmacology, Vol.96, Iss.3-4, 2015-08, pp. : 163-166

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cyclophilin Inhibitors as a Novel HCV Therapy

By Tang Hengli  

Viruses, Vol. 2, Iss. 8, 2010-08 ,pp. : 1621-1634

MDPI

Access to resources Recommend Favorite

A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection

By Kishida Yutaka   Imaizumi Naohiko   Tanimura Hirohisa   Kashiwamura Shinichiro   Kashiwagi Toru  

International Journal of Molecular Sciences, Vol. 17, Iss. 3, 2016-03 ,pp. : 350-350

MDPI

Access to resources Recommend Favorite

Synthesis, Anti-HCV, Antioxidant and Reduction of Intracellular Reactive Oxygen Species Generation of a Chlorogenic Acid Analogue with an Amide Bond Replacing the Ester Bond †

By Wang Ling-Na   Wang Wei   Hattori Masao   Daneshtalab Mohsen   Ma Chao-Mei  

Molecules, Vol. 21, Iss. 6, 2016-06 ,pp. : 737-737

MDPI

Access to resources Recommend Favorite

Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors

By Latronico Tiziana   Mascia Claudia   Pati Ilaria   Zuccala Paola   Mengoni Fabio   Marocco Raffaella   Tieghi Tiziana   Belvisi Valeria   Lichtner Miriam   Vullo Vincenzo   Mastroianni Claudio Maria   Liuzzi Grazia Maria  

International Journal of Molecular Sciences, Vol. 17, Iss. 4, 2016-03 ,pp. : 455-455

MDPI

Access to resources Recommend Favorite

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors

By Kanda Tatsuo   Yasui Shin   Nakamura Masato   Suzuki Eiichiro   Arai Makoto   Ooka Yoshihiko   Ogasawara Sadahisa   Chiba Tetsuhiro   Saito Tomoko   Haga Yuki   Takahashi Koji   Sasaki Reina   Wu Shuang   Nakamoto Shingo   Tawada Akinobu   Maruyama Hitoshi   Imazeki Fumio   Kato Naoya   Yokosuka Osamu  

International Journal of Molecular Sciences, Vol. 18, Iss. 5, 2017-04 ,pp. : 906-906

MDPI

Access to resources Recommend Favorite